Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging
MetadataShow full item record
CitationMikula, Hannes, Shawn Stapleton, Rainer H. Kohler, Claudio Vinegoni, and Ralph Weissleder. 2017. “Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging.” Theranostics 7 (5): 1257-1265. doi:10.7150/thno.18238. http://dx.doi.org/10.7150/thno.18238.
AbstractHerein we describe fluorescent derivatives of vemurafenib to probe therapeutic BRAF inhibition in live cells and in vivo. The compounds were evaluated and compared by determining target binding, inhibition of mutant BRAF melanoma cell lines and live cell imaging. We show that vemurafenib-BODIPY is a superior imaging drug to visualize the targets of vemurafenib in live cells and in vivo in non-resistant and resistant melanoma tumors.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32630440
- HMS Scholarly Articles